发明名称 |
MN/CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED FROM MN/CA IX-DEFICIENT MICE AND METHODS OF USE |
摘要 |
Disclosed herein among other MN/CA IX-related inventions are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, preferably monoclonal antibodies and immunoreactive fragments and engineered variants thereof. Subsets of the new antibodies are to either the proteoglycan-like (PG) domain or to the carbonic anhydrase (CA) domain of MN/CA IX, and methods are provided by which antibodies can be prepared to the other MN/CA IX domains. Such new MN/CA IX-specific antibodies, fragments and variants are useful diagnostically/prognostically and therapeutically for cancer and precancer. Particularly preferred are the new monoclonal antibodies, fragments and variants that are specific for the non-immunodominant epitopes of MN/CA IX, which antibodies are, among other uses, useful to detect soluble MN/CA IX (s-CA IX) in body fluids, alone but preferably in combination with antibodies specific to the immunodominant epitopes of MN/CA IX, for example, in a sandwich assay. |
申请公布号 |
US2015266971(A1) |
申请公布日期 |
2015.09.24 |
申请号 |
US201414529138 |
申请日期 |
2014.10.30 |
申请人 |
Pastorek Jaromir;Pastorekova Silvia;Zatovicova Miriam;Zavada Jan;Ortova Gut Marta;Zavadova Zuzanna |
发明人 |
Pastorek Jaromir;Pastorekova Silvia;Zatovicova Miriam;Zavada Jan;Ortova Gut Marta;Zavadova Zuzanna |
分类号 |
C07K16/32;C07K16/40 |
主分类号 |
C07K16/32 |
代理机构 |
|
代理人 |
|
主权项 |
1. A monoclonal antibody or antigen-binding fragment thereof that specifically binds to a non-immuno dominant epitope of MN//CA IX protein or MN/CA IX polypeptide, wherein said antibody is generated from MN/CA IX-deficient mice and wherein said antibody does not compete for binding to MN/CA IX with monoclonal antibodies MN7, M75 or MN12, with the proviso that the antibody does not bind to the proteoglycan-like (PG) domain of MN/CA IX, and wherein said epitope is selected from epitopes
(a) within the carbonic anhydrase (CA) domain having the amino acid sequence of SEQ ID NO: 9, (b) within the CA domain having the amino acid sequence of SEQ ID NO: 101, (c) within the CA domain having the amino acid sequence of SEQ ID NO: 67, (d) within the CA domain having the amino acid sequence SEQ ID NO: 69, (e) within the transmembrane domain (TM) having the amino acid sequence of SEQ ID NO: 6, and (f) within the intracellular domain (IC) having the amino acid sequence of SEQ ID NO: 7. |
地址 |
Bratislava SK |